Disc Medicine raises $62.5M in registered direct offering led by Bain Capital Life Sciences

Disc Medicine, Inc.

Gross proceeds $62.5M from offering of 1,488,166 shares at $23.00 and pre-funded warrants for 1,229,224 shares.
Bain Capital Life Sciences contributed $50M; existing investors Access Biotechnology and OrbiMed also participated.
Net proceeds to fund clinical development of bitopertin, DISC-0974, MWTX-003 and for working capital.
Offering expected to close on or about February 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Disc Medicine, Inc. entered into Purchase Agreement with the investors identified therein valued at approximately $62.5 million (effective 2023-02-13).

Action: entry
Agreement: equity purchase
Counterparty: the investors identified therein
Value: approximately $62.5 million
Effective: 2023-02-13

Exact text from the filing

On February 13, 2023, Disc Medicine, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investors identified therein.

View on SEC.gov

Browse all material agreements →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-037151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.